Bin-Yan Zhong

List of Publications by Year
in descending order

44 papers	524 citations	933447 10 h-index	752698 20 g-index
45 all docs	45 docs citations	45 times ranked	592 citing authors

#	Article	IF	Citations
1	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology and Hepatology, 2019, 4, 721-730.	8.1	105
2	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surgery and Nutrition, 2021, 10, 661-671.	1.5	46
3	Bariatric Embolization of the Left Gastric Arteries for the Treatment of Obesity: 9-Month Data in 5 Patients. Obesity Surgery, 2018, 28, 907-915.	2.1	44
4	Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Frontiers in Oncology, 2020, 10, 1196.	2.8	34
5	Risk Prediction of New Adjacent Vertebral Fractures After PVP for Patients with Vertebral Compression Fractures: Development of a Prediction Model. CardioVascular and Interventional Radiology, 2017, 40, 277-284.	2.0	27
6	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 330-338.	0.5	24
7	Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib. Frontiers in Oncology, 2020, 10, 593292.	2.8	23
8	Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. American Journal of Roentgenology, 2021, 217, 933-943.	2.2	22
9	Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study. Translational Oncology, 2021, 14, 101034.	3.7	20
10	Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology, 2017, 284, 583-592.	7.3	19
11	Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 657512.	2.8	16
12	Prognostic Performance of Albuminâ€“Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Oncology, 2020, 10, 525461.	2.8	15
13	Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	14
14	Risk Prediction for Early Biliary Infection after Percutaneous Transhepatic Biliary Stent Placement in Malignant Biliary Obstruction. Journal of Vascular and Interventional Radiology, 2019, 30, 1233-1241.e1.	0.5	10
15	Single-Centre Retrospective Training Cohort Using Artificial Intelligence for Prognostic Prediction of Encephalopathy, Mortality, and Liver Dysfunction after Early TIPS Creation. CardioVascular and Interventional Radiology, 2021, 44, 1597-1608.	2.0	9
16	Bariatric Arterial Embolization for Obesity: A Review of Early Clinical Evidence. CardioVascular and Interventional Radiology, 2018, 41, 1639-1647.	2.0	8
17	Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. Journal of Clinical and Translational Hepatology, 2022, 10, 740-747.	1.4	7
18	Percutaneous Vertebroplasty for Symptomatic Schmorl's Nodes: 11 Cases with Long-term Follow-up and a Literature Review. Pain Physician, 2017, 20, 69-76.	0.4	7

#	Article	IF	Citations
19	A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. Journal of Vascular and Interventional Radiology, 2016, 27, 1288-1297.	0.5	6
20	Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective. Chinese Clinical Oncology, 2019, 8, 60-60.	1.2	6
21	125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. CardioVascular and Interventional Radiology, 2020, 43, 196-203.	2.0	6
22	Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE. CardioVascular and Interventional Radiology, 2020, 43, 1460-1467.	2.0	6
23	Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 602700.	2.8	6
24	Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Frontiers in Molecular Biosciences, 2021, 8, 618050.	3.5	6
25	Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. CardioVascular and Interventional Radiology, 2021, 44, 63-72.	2.0	5
26	Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 615133.	3.5	5
27	Performance of artificial intelligence for prognostic prediction with the albumin-bilirubin and platelet-albumin-bilirubin for cirrhotic patients with acute variceal bleeding undergoing early transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e153-e160.	1.6	5
28	ANVCFV Score System: Assessment for Probability of New Vertebral Compression Fractures after Percutaneous Vertebroplasty in Patients with Vertebral Compression Fractures. Pain Physician, 2015, 18, E1047-57.	0.4	5
29	Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World Journal of Gastrointestinal Surgery, 2022, 14, 528-537.	1.5	5
30	Nomogram for Predicting Intradiscal Cement Leakage Following Percutaneous Vertebroplasty in Patients with Osteoporotic Related Vertebral Compression Fractures. Pain Physician, 2017, 20, E513-E520.	0.4	4
31	Comparison of catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy for subacute iliofemoral deep vein thrombosis. Phlebology, 2020, 35, 589-596.	1.2	3
32	Response to Letter of â€œLeft Gastric Artery Embolization for Weight Lossâ€”a Deadend Procedureâ€• Obesity Surgery, 2018, 28, 3625-3626.	2.1	1
33	Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. CardioVascular and Interventional Radiology, 2018, 41, 1867-1876.	2.0	1
34	Research progress of bariatric embolization for treatment of obesity. Chinese Medical Journal, 2019, 132, 880-882.	2.3	1
35	Changes in IR from 2007 to 2017 in China. Journal of Vascular and Interventional Radiology, 2020, 31, 1449-1452.	0.5	1
36	Impact of COVID-19 Pandemic on Intervals and Outcomes of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	1

#	Article	IF	Citations
37	Does Sorafenib Fit for All?. Radiology, 2017, 284, 919-921.	7.3	0
38	Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology, 2018, 288, 636-636.	7.3	0
39	Bariatric Arterial Embolization for Overweight Patients: A New Exploration for Ideal Patients?. CardioVascular and Interventional Radiology, 2019, 42, 1048-1049.	2.0	0
40	Prognostic nomogram on admission predicting progression for patients with nonsevere COVID-19. Fundamental Research, 2021, 1, 111-116.	3.3	0
41	Application of radiomics in hepatocellular carcinoma: A review. Artificial Intelligence in Medical Imaging, 2021, 2, 64-72.	0.6	0
42	Reply to: Percutaneous Vertebral Augmentation for the Treatment of Symptomatic Schmorlâ€™s Nodes: Our Viewpoint and Experience. Pain Physician, 2017, 3, E474-E475.	0.4	0
43	Deep Learning Predicts Overall Survival of Patients with Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib: A Multicenter Study. SSRN Electronic Journal, 0, , .	0.4	0
44	Reply to: Percutaneous Vertebral Augmentation for the Treatment of Symptomatic Schmorl's Nodes: Our Viewpoint and Experience. Pain Physician, 2017, 20, E474-E475.	0.4	0